Laidlaw & Company, which underwrote the recent IPO for Therapix Biosciences (NASDAQ: TRPX), has initiated research coverage of the company, giving it a “Buy” rating and suggesting a price...

Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome TEL AVIV, Israel, May...

Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer TEL AVIV, Israel, May 3, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX) (“Therapix”), a specialty clinical...

Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology Agreement Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings for Mild Cognitive Impairment...

Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing TEL AVIV, Israel, March 22, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (NASDAQ: TRPX) (TASE: THXBY), a...

Therapix Biosciences Provides Portfolio Update TEL AVIV, Israel, January 11, 2017 /PRNewswire/ — Therapix Biosciences (OTCQB: THXBY) (TASE: THXBY.TA), a clinical-stage pharma company specializing in the development of cannabinoid-based...

Therapix Biosciences announces enrollment of the first patient for clinical trial at Yale University for treating Tourette’s syndrome using cannabinoid-based drug TEL AVIV, Israel, January 4, 2017 /PRNewswire/ —...